Fennec Pharmaceuticals (TSX:FRX) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals ROE % Adjusted to Book Value?

Fennec Pharmaceuticals's ROE % for the quarter that ended in Dec. 2023 was 0.00%. Fennec Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Fennec Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.

Fennec Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Fennec Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals ROE % Adjusted to Book Value Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-7.07

-13.82

-10.71

Fennec Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Fennec Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Fennec Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Fennec Pharmaceuticals ROE % Adjusted to Book Value Calculation

Fennec Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Fennec Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Fennec Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (TSX:FRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.